Search alternatives:
mean decrease » a decrease (Expand Search)
μ decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
50 μ » 10 μ (Expand Search), 5 μ (Expand Search)
mean decrease » a decrease (Expand Search)
μ decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
50 μ » 10 μ (Expand Search), 5 μ (Expand Search)
-
221
-
222
-
223
Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer
Published 2021“…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
-
224
Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer
Published 2021“…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
-
225
Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer
Published 2021“…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
-
226
Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer
Published 2021“…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
-
227
Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer
Published 2021“…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
-
228
-
229
-
230
-
231
-
232
-
233
-
234
-
235
-
236
-
237
-
238
-
239
-
240